Holen Sie sich die Stockscreener-App
4.3899
5.69%
-0.0951
Lixte Biotechnology Holdings Inc Aktie (LIXT) Neueste Nachrichten
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Lixte Biotechnology Holdings, Inc. (LIXT) Latest Stock News & Headlines - Yahoo Finance
LIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer Treatment - NewMediaWire
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment - TipRanks
LIXTE Biotechnology Advances Precision Oncology with Novel PP2A Inhibitor LB-100 - citybuzz -
LIXT Lixte posts Q4 2024 negative EPS of 27 cents and zero revenue, with shares unchanged today.EBITDA Margin - Cổng thông tin điện tử tỉnh Tây Ninh
LIXT Lixte Biotechnology Holdings Inc. shares gain 6.87 percent on positive investor reaction to Q4 2024 earnings release.Professional Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape - The Globe and Mail
Lixte (LIXT) Stock Volume Stability (Bearish Sentiment) 2026-04-20Crowd Entry Signals - Cổng thông tin điện tử tỉnh Lào Cai
LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape - NewMediaWire
Why Cardio Diagnostics Holdings (NASDAQ: CDIO) Is ‘One to Watch’ - Financial-News.co.uk
Lixte Biotechnology stock (US53833K1060): Is its PP2A cancer focus strong enough to unlock breakthro - AD HOC NEWS
Lixte Biotechnology Updates Executive Equity Compensation With RSUs - The Globe and Mail
Lixte Biotechnology Holdings, Inc. Files Form 8-K with SEC Detailing Restricted Share Unit Awards and Company Information (April 2026) - Minichart
Lixte Biotechnology Holdings cancels options, grants RSUs to executives and directors - Investing.com India
LIXTE Biotechnology’s LB-100 Represents Novel Approach to Enhancing Cancer Therapies - citybuzz -
Lixte Biotechnology Holdings cancels options, grants RSUs to executives and directors By Investing.com - Investing.com South Africa
Lixte Biotechnology (LIXT) CEO cancels 350K options for shares - Stock Titan
Lixte (LIXT) CFO cancels 50K options, receives 50K RSUs - Stock Titan
LIXTE (LIXT) director cancels 25K options and receives 25K RSUs - Stock Titan
LIXTE (LIXT) director cancels 25K options, receives 25K RSUs vesting immediately - Stock Titan
Lixte (LIXT) cancels insider stock options and grants fully vested RSUs - Stock Titan
Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built - The Globe and Mail
Lixte Biotechnology Holdings, Inc. (LIXTW) - Minichart
"NextEpochMarket company news.lhl"Results on X | Live Posts & Updates - x.com
LIXTE Biotechnology Reports Promising Interim Ovarian Cancer Trial Results at SGO Conference - citybuzz -
LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - USA Today
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - NewMediaWire
Options Flow: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity Warrant2026 Macro Impact & AI Forecast Swing Trade Picks - baoquankhu1.vn
Promising Clinical Trial Results for Lixte Biotechnology (LIXT) - GuruFocus
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference - GlobeNewswire
Geopolitics Watch: How volatile is Lixte Biotechnology Holdings Inc stock2026 Catalysts & Risk Controlled Daily Trade Plans - baoquankhu1.vn
LIXTE Biotechnology Expands Cancer Treatment Strategy with Acquisition and Clinical Advancements - citybuzz -
Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships - NewMediaWire
Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships - TipRanks
Aug Reactions: What is the cash position of Lixte Biotechnology Holdings Inc2026 Fundamental Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Retail Trends: What are the future prospects of Mineralys Therapeutics Inc2026 Sentiment & Community Shared Stock Ideas - baoquankhu1.vn
Lixte Biotech Advances Precision Oncology Strategy with LB-100 Therapy and Expanded Partnerships - citybuzz -
Valuation Update: Is Airship AI Holdings Inc part of any ETFPortfolio Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Risk Off: Is Lixte Biotechnology Holdings Inc attractive for institutional investors2026 Price Targets & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
ETF Watch: Is Lixte Biotechnology Holdings Inc affected by consumer sentiment2026 Technical Overview & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Is Lixte (LIXT) Stock Underperforming | Price at $3.08, Up 0.98%Crowd Sentiment Stocks - Newser
LIXT Technical Analysis & Stock Price Forecast - Intellectia AI
Investor Mood: Is Lixte Biotechnology Holdings Inc stock forming a triangle pattern2026 Snapshot & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
Lixte Biotechnology Holdings, Inc. (LIXTW) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year - newmediawire.com
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year - Financial-News.co.uk
LIXTE Biotechnology’s LB-100 May Transform Cancer Treatment—Yet Time Remains the Deciding Factor - bitget.com
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):